MINI REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1666343
This article is part of the Research TopicNeural influences on tumor immunity: Exploring neuroimmunology in cancerView all 15 articles
Neurotrophic Factors as Double-Edged Swords in Osteosarcoma: Drivers of Tumor Growth and Immune Remodeling
Provisionally accepted- Shengjing Hospital of China Medical University Department of Orthopedics Surgery, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Neurotrophic factors, once considered exclusive guardians of neuronal integrity, are increasingly recognised as pivotal regulators of osteosarcoma biology. Their paradoxical enhancement of malignant fitness and an immunosuppressive microenvironment complicates therapy, with metastatic survival remaining stubbornly low. Recent mechanistic studies reveal that ligand-dependent NGF–TrkA, BDNF–TrkB and GDNF–RET circuits intersect with MEK/ERK, PI3K/AKT and STAT3 pathways to ignite proliferation, invasion and metastatic spread. Concurrently, neurotrophin signalling recalibrates macrophage polarity, dampens cytotoxic T-cell function and orchestrates neural-immune feedback loops that shield tumours from surveillance. Harnessing this duality demands an integrative strategy. We synthesise tumour-intrinsic and extrinsic neurotrophic axes, delineate neuro-immune crosstalk, and highlight interventions—TRK/RET inhibitors, CSF1R blockade, β-adrenergic antagonists—aimed at converting this liability into therapeutic leverage. By framing neurotrophic factors as double-edged swords, this review provides a conceptual and practical roadmap for exploiting their vulnerabilities to improve outcomes in osteosarcoma.
Keywords: neurotrophic factors, Osteosarcoma, immune microenvironment, neuro-immune crosstalk, targeted therapy, Immunotherapy
Received: 15 Jul 2025; Accepted: 23 Sep 2025.
Copyright: © 2025 Lei and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lei Li, lileispine@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.